Targets › RPS6
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Other, Oncology; next expected readout Jun 2027.
Component of the 40S small ribosomal subunit. Plays an important role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. (UniProt, P62753)
Open in Phaseline: the race on RPS6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals | Elx-02 80S Ribosome modulator | RPSA, RPS27, RPS6, RPS2, RPS3 | Phase 2 | Alport Syndrome, X-Linked | Jun 2027 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Ataluren 80S Ribosome modulator | RPSA, RPS27, RPS6, RPS2, RPS3 | Phase 1 | Colorectal Cancer | – |
Alport Syndrome, X-Linked (1) Colorectal Cancer (1)
small molecule (1), antibody (1)
Eloxx Pharmaceuticals (1) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.